WuXi Biologics

WuXi Biologics is owned by HiberCell. HiberCell has a direct presence in 2 countries.

HiberCell has 7 subsidiaries including Genuity Science, WuXi Advanced Therapies and WuXi AppTec.

View the org chart displaying its 39 main executives

Most searched biographies at WuXi Biologics

• Zhisheng Chen, Chief Executive Officer and Director
• William Keller, Independent Non-Executive Director
• Kenneth Hitchner, Independent Non-Executive Director

Popular executive movements at WuXi Biologics

• Sherry Gu who is Vice President, Chemistry, Manufacturing and Controls, will be promoted to Chief Technology Officer and Executive Vice President of Global Biologics Development on Mar. 31, 2024  (posted on January 16 2024).
• Jue Chen has joined the company as Independent Non-Executive Director  (posted on August 17 2023).

Create your alert
to follow the executive moves at WuXi Biologics.

HiberCell has 2,279 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
• Histogen has filed for bankruptcy protection  (posted on April 19 2024).
• Bruker has announced the acquisition of NanoString Technologies  (posted on April 18 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Vik Bajaj - Director at Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by WuXi Biologics

Social media about WuXi Biologics

• WuXi Biologics on Wikipedia, Google News & Yahoo Finance
• WuXi Biologics on LinkedIn, Twitter & YouTube

Contact by email its executives including Jue Chen

Call WuXi Biologics at +86 400...

View the org chart

Register to receive your alert

Report an error